Bestzyme’s sweet revolution: Mellia Brazzein wins FDA green light to transform global sugar markets!

In a landmark development for the future of sugar alternatives, Bestzyme, a subsidiary of GenScript Biotech Corporation, announced on April 26, 2025, that its flagship sweetener, Mellia™ Brazzein, has received a “No Questions” letter from the U.S. Food and Drug Administration (FDA), affirming its Generally Recognized as Safe (GRAS) status. This official regulatory milestone not only underscores Mellia™ Brazzein’s safety but also signals its readiness for large-scale deployment across global food and beverage markets seeking innovative sugar-reduction solutions.

The FDA’s GRAS approval comes after Bestzyme’s successful completion of the Self-GRAS certification process in July 2024, which set the foundation for official regulatory recognition. Bestzyme highlighted that this endorsement validates Mellia™ Brazzein’s compliance with rigorous safety and regulatory frameworks, positioning the product at the forefront of the natural sweetener industry’s ongoing evolution. With the FDA clearance, Mellia™ Brazzein is now authorized for use as a general-purpose sweetener across a broad spectrum of food and beverage applications.

What is Mellia™ Brazzein and Why is it Considered a Game-Changer?

Mellia™ Brazzein is derived from brazzein, a naturally occurring sweet-tasting protein found in the fruit of the West African plant Oubli (Pentadiplandra brazzeana Baillon). Bestzyme has pioneered the sustainable production of this protein through advanced precision fermentation techniques, enabling its industrial-scale manufacture without reliance on traditional plant extraction methods. This development marks a significant leap toward sustainability and supply chain stability in the high-growth alternative sweeteners sector.

Featuring a pure sweet taste profile with high sweetness intensity and flavor-modifying capabilities, Mellia™ Brazzein is poised to become a cornerstone of next-generation sugar reduction strategies. The protein’s molecular structure allows for rapid digestion into amino acids without impacting blood glucose levels or disturbing the gut microbiome, offering a compelling alternative for health-conscious consumers who are increasingly wary of artificial sweeteners and high-calorie sugar consumption.

How Does Mellia™ Brazzein Address Growing Global Demand for Sugar Reduction?

As public health campaigns and consumer awareness around sugar consumption intensify globally, the food and beverage industry faces mounting pressure to reformulate products with healthier alternatives. Bestzyme’s Mellia™ Brazzein arrives at a critical juncture, providing manufacturers a zero-calorie sweetener option that aligns with trends favoring natural, minimally processed ingredients.

Industry analysts have noted that Mellia™ Brazzein’s potential application across beverages, dairy products, confectionery, chocolate, health supplements, and catering services significantly broadens its commercial relevance. As nations introduce sugar taxes and regulatory frameworks to curb sugar intake, the availability of a natural sweetener that meets consumer expectations on taste and health benefits could substantially reshape product portfolios across multiple food categories.

How Will FDA Approval Impact Bestzyme’s Strategic Position Globally?

The FDA’s “No Questions” letter effectively grants Bestzyme access to the lucrative U.S. food market, one of the largest and most influential globally. It also enhances the company’s credibility in other regulatory jurisdictions where GRAS designation is viewed as a gold standard for product safety. Bestzyme indicated that this milestone paves the way for Mellia™ Brazzein to penetrate international markets, catering to global players eager to innovate in the low- and no-sugar categories.

The company further shared that Mellia™ Brazzein’s entry is a key pillar in its broader functional protein product pipeline strategy. Bestzyme is committed to expanding its portfolio with more bio-based, health-enhancing ingredients that meet the world’s accelerating demand for sustainable and wellness-driven solutions.

What is Bestzyme’s Vision for Future Growth in the Bio-Based Sweeteners Market?

Bestzyme emphasized that Mellia™ Brazzein is not just a product launch, but a step forward in redefining food ingredient innovation through synthetic biology. Leveraging its proprietary platform that integrates molecular design, strain engineering, and scalable production processes, Bestzyme plans to intensify investments in functional proteins, enzymes, and biopharmaceutical raw materials.

The company reaffirmed its goal of promoting green manufacturing practices by minimizing environmental footprints, supporting a transition towards more sustainable industrial ecosystems. In its latest communication, Bestzyme articulated a vision where bio-based innovations like Mellia™ Brazzein help build healthier, more sustainable lifestyles for global consumers, all while aligning with environmental, social, and governance (ESG) frameworks increasingly adopted by forward-looking corporations.

Although Bestzyme itself is not publicly traded independently—being a subsidiary of GenScript Biotech Corporation—this development significantly enhances GenScript’s positioning within the synthetic biology and biotechnology sectors. Market sentiment around GenScript Biotech Corporation (listed on the Hong Kong Stock Exchange) remains broadly positive, with analysts noting the company’s expanding footprint in high-margin, next-generation biotechnology products.

The successful commercialization of Mellia™ Brazzein could translate into new revenue streams, further diversifying GenScript’s portfolio beyond traditional biopharma and contract research services. Investors closely watching the nutraceuticals, food innovation, and synthetic biology spaces may view GenScript’s backing of Bestzyme as a positive catalyst for long-term growth, especially amid rising institutional interest in sustainable food technologies.

In the current context of growing demand for health-focused and sustainable products, regulatory validations such as the FDA GRAS status for Mellia™ Brazzein could serve as pivotal points that drive increased investor confidence in GenScript’s strategic initiatives. Industry sentiment toward bio-based food innovations continues to trend upward, buoyed by global health, environmental, and regulatory tailwinds.